Question 1

How much booked-orderbook + fill-finish-batches-released + right-first-time + net-ARR + first-Lonza/Catalent-Novo Dec-2024/Samsung Biologics/WuXi Biologics BIOSECURE Sep-2024-cautionary/Fujifilm Diosynth/Boehringer BioXcellence/Thermo Patheon/Recipharm-EQT/Piramal/Siegfried/PCI Pharma-Kohlberg/Cambrex-Permira/Vetter/Bushu/Novasep-Axplora-Ardian/AGC Biologics/Rentschler/Alcami/GRAM/IDT/Baxter-Simtra-Advent-Warburg 2023/Emergent BioSolutions J&J-Janssen 2021-cross-contamination-precedent/Curia-GHO-Ampersand/Sartorius/Danaher-Cytiva/MilliporeSigma/Bio-Techne/Repligen/Solventum-April-2024/West/Datwyler/Aptar/SCHOTT Pharma/Gerresheimer/Nipro/Stevanato/Corning-Valor/Aldevron-Danaher/Charles River/Oxford Biomedica/Kymriah-Novartis/Fujifilm CDI/Cognate-CRL/Yposkesi-SK pharmteco/Cobra-CRL/Batavia/Andelyn/CBM-Discovery Labs/Forge Bio-Ajinomoto/Exothera/Elevate Bio/National Resilience partnership + FDA 21 CFR Part 210+211 cGMP+Part 600 Biologics+Part 820 QSR+Q3 2024 QMSR-ISO 13485-Feb-2026+ICH Q7+Q8+Q9+Q10+Q11+Q12+Q13-Continuous-Manufacturing 2023+FDA Annex 1 Aug-2023+ISO 14644 Cleanroom+ISO 13408 Aseptic+GAMP 5 Second Edition Jul-2022+DSCSA Nov-2024 Enforcement-Discretion Q3 2024+BIOSECURE Act H.R. 8333 House-Passed Sep-2024 WuXi-BGI cautionary discipline do AI CDMO-CMO-fill-finish-sterile startups need for Series A in 2026?

Accepted Answer

Series A gate: $50-500M booked-orderbook + 500-10000 fill-finish batches-released + >95% right-first-time + $5-50M net-ARR + Lonza LONN.SW+Q3 2024 Vacaville-Roche $1.2B+2023 Ibex Solutions divest cautionary/Catalent-Novo Dec-2024 $16.5B take-private-closed+FTC-DOJ HSR Q3 2024 cleared/Samsung Biologics 207940.KS+Q3 2024 Plant-5 online/WuXi Biologics 2269.HK+Q3 2024 BIOSECURE Sep-2024 cautionary/WuXi AppTec 603259.SS BIOSECURE cautionary/Fujifilm Diosynth+Q3 2024 Holly Springs NC+Denmark/Boehringer Ingelheim BioXcellence/Thermo Patheon $TMO+Q3 2024 Greenville NC/Recipharm-EQT 2021 SEK 23B+Q3 2024 restructure cautionary/Piramal Pharma 543635.BO/Siegfried SFZN.SW/AGC Biologics/Rentschler/Novasep-Axplora-Ardian 2021/IDT Biologika-KfW 2020 + large-molecule mAb+ADC+bioconjugate CDMO+off-take + first-FDA 21 CFR Part 600 Biologics-or-ICH Q7 API-or-Q8-or-Q10-or-Annex 1 Aug-2023-or-Q13 Continuous-Manufacturing-line + first-Emergent BioSolutions J&J-Janssen 2021 Bayview cross-contamination precedent-or-Kymriah-Novartis Advate 2019 GMP-warning precedent-or-BIOSECURE H.R. 8333 Sep-2024-line (large-molecule mAb+ADC+bioconjugate CDMO precedent), $50-500M booked-orderbook + Cambrex-Permira 2019/PCI Pharma-Kohlberg 2020+Q3 2024 fill-finish/Alcami-Madison Dearborn 2018+Q3 2024 sterile-fill+API/Baxter-Simtra BioPharma-Advent-Warburg 2023 $4.25B carve-out/Grand River Aseptic Manufacturing-Arlington Capital+Q3 2024 GRAM expansion/Vetter Pharma/Bushu Pharmaceuticals/ProJect Pharmaceutics/Curia Global-GHO-Ampersand 2021 Q3 2024 layoffs+Corden Pharma divest exploration cautionary + small-molecule API+HPAPI+solid-oral+topical CMO+CDMO+off-take + first-ICH Q7 API-or-Q11 API Development-line+first-ANDA vs 505(b)(2) vs BLA vs NDA pathway-line (small-molecule API+HPAPI+solid-oral+topical CMO+CDMO precedent), $50-500M booked-orderbook + West $WST+Q3 2024 GLP-1 fill-finish/Datwyler DAE.SW/Aptar $ATR+Q3 2024 nasal drug-delivery-GLP-1/SCHOTT Pharma XVAC.DE 2023 IPO/Gerresheimer $GXI.DE+Q3 2024 GLP-1 syringe/Nipro 8086.T/Stevanato $STVN+Q3 2024 GLP-1 syringe/Corning $GLW Valor Glass+Q3 2024 pharma-glass+Corning-Merck Q3 2024 $250M/Bausch+Lomb $BLCO/3M-Solventum $SOLV April-2024/Sartorius $SRT.DE+Q3 2024 profit-warning cautionary/Danaher-Cytiva DHR+Q3 2024 bioprocessing-recovery/MilliporeSigma MRK.DE/Bio-Techne $TECH/Repligen $RGEN+Q3 2024 recovery/Eppendorf/Tecan TECN.SW/Sotax + fill-finish+aseptic+isolator+RABS+single-use+lyo+sterile-injectables+prefilled-syringe+auto-injector+on-body+pen+vial+cartridge+BFS+CCIT+off-take + first-FDA Annex 1 Aug-2023-or-ISO 14644 Cleanroom-or-ISO 13408 Aseptic-or-ISO 8871 Elastomers-or-ISO 11607 Packaging-line+first-CSV+GAMP 5 Second Edition Jul-2022+ALCOA+Data Integrity FDA 483s-Warning Letters-line (fill-finish+aseptic+isolator+RABS+single-use+lyo+sterile-injectables+prefilled-syringe+auto-injector+pen+vial+cartridge+BFS+CCIT precedent), or $50-500M booked-orderbook + Aldevron-Danaher 2021 $9.6B+Q3 2024 pDNA/Charles River $CRL+Q3 2024 restructure cautionary+Vigene 2021 $350M/Oxford Biomedica $OXB.L+Q3 2024 restructure+Homology 2023 cautionary/Fujifilm CDI/Cognate BioServices-CRL 2021/Yposkesi-SK pharmteco 2021/Cobra Biologics-CRL 2021/Batavia-BioLogics 2022/Andelyn-Nationwide Children's Q3 2024/Center for Breakthrough Medicines-Discovery Labs 2021+Q3 2024 restructure+CBM Ch-11-avoided cautionary/Forge Biologics-Ajinomoto 2023 $620M/Exothera-Univercells 2020/Elevate Bio-D1-Softbank Vision Fund-Matrica 2023+Q3 2024 GMP+ National Resilience-Arch-8VC-NEA 2020+Q3 2024 restructure+2023 layoffs cautionary/Novartis-Kymriah Morris Plains+Q3 2024 GMP-warning-Advate 2019 precedent cautionary/Bristol Myers-Celgene-Juno Seattle + mRNA+viral-vector+plasmid-DNA+cell-gene+CGT-CDMO+off-take + first-FDA CBER-line+first-ICH Q5A viral-safety-or-Q5B expression-line, plus US FDA CDER+CBER+CDRH+ORA+21 CFR Part 4 Combination Products+Part 11 Electronic Records+Q3 2024 QMSR-ISO 13485-harmonization Feb-2026+ICH Q9+Q14+FDA Real Time Release Testing+PAT+QbD+PDA TR 66+ISPE Baseline Guides+ISO 27001+SOC 2+EU Annex 1 Aug-2023+EudraLex Volume 4+EMA CHMP+CVMP+PRAC+CAT+COMP+PDCO+MHRA+PMDA+NMPA+ANVISA+Health Canada+WHO PQ+USP+Ph. Eur.+JP+CDER FDORA 2022+DSCSA Nov-2024 Enforcement-Discretion Q3 2024+BIOSECURE H.R. 8333 Sep-2024+CHIPS+Science Act 2022+IRA Drug-Pricing 2022+Medicare Negotiation+EO 14081 Bioeconomy Sep-2022+NIH+BARDA+ASPR+DoD DARPA+WHO+CEPI+GAVI+EU Critical Medicines Act 2024 proposed+EU Pharmaceutical Package Reform Q3 2024+CTIS Jan-2022+EU IVDR May-2022+MDR May-2021 discipline day-one.

Question 2

Which investors lead AI CDMO-CMO-fill-finish-sterile rounds in 2026?

Accepted Answer

PE+strategic+sovereign: Novo Holdings-Catalent Dec-2024 $16.5B take-private-closed+FTC-DOJ HSR Q3 2024 cleared, Advent-Warburg Pincus-Baxter-Simtra BioPharma 2023 $4.25B carve-out, EQT-Recipharm 2021 SEK 23B take-private+Q3 2024 restructure cautionary, Permira-Cambrex 2019, Kohlberg-Mubadala-PCI Pharma 2020+Q3 2024 fill-finish, Madison Dearborn-Alcami 2018+Q3 2024 sterile-fill+API, Arlington Capital-GRAM+Q3 2024 GRAM expansion, GHO Capital-Ampersand-Curia 2021+Q3 2024 layoffs+Corden Pharma divest exploration cautionary, Ardian-Axplora-Novasep 2021, KfW Bavaria-IDT Biologika 2020, D1-Softbank Vision Fund-Matrica-Elevate Bio 2023+Q3 2024 GMP+2023 SoftBank restructure cautionary, Arch Venture-8VC-NEA-National Resilience 2020+Q3 2024 restructure+2023 layoffs cautionary, Danaher-Aldevron 2021 $9.6B+Q3 2024 pDNA, Danaher-Cytiva DHR+Q3 2024 bioprocessing-recovery, SK pharmteco-Yposkesi 2021, Charles River-Cognate-Cobra-Vigene 2021+Q3 2024 restructure cautionary, Ajinomoto-Forge Biologics 2023 $620M, Discovery Labs-CBM 2021+Q3 2024 restructure+CBM Ch-11-avoided cautionary, Univercells-Exothera 2020, Nationwide Children's-Andelyn Q3 2024, BioLogics-Batavia 2022. Public: Lonza LONN.SW, Samsung Biologics 207940.KS, WuXi Biologics 2269.HK+WuXi AppTec 603259.SS BIOSECURE H.R. 8333 Sep-2024 cautionary, Thermo Patheon $TMO+Q3 2024 Greenville NC, Fujifilm Diosynth+Q3 2024 Holly Springs+Denmark, Boehringer BioXcellence, Piramal Pharma 543635.BO, Siegfried SFZN.SW, AGC Biologics, Sartorius $SRT.DE+Q3 2024 profit-warning cautionary+2023 Q4 profit-warning+bioprocessing-destocking, MilliporeSigma MRK.DE, Bio-Techne $TECH, Repligen $RGEN+Q3 2024 recovery, 3M-Solventum $SOLV April-2024, West $WST+Q3 2024 GLP-1, Datwyler DAE.SW, Aptar $ATR+Q3 2024 nasal-GLP-1, SCHOTT Pharma XVAC.DE 2023 IPO, Gerresheimer $GXI.DE+Q3 2024 GLP-1, Nipro 8086.T, Stevanato $STVN+Q3 2024 GLP-1, Corning $GLW Valor+Q3 2024+Corning-Merck Q3 2024 $250M, Bausch+Lomb $BLCO, Emergent BioSolutions $EBS+2021 J&J-Janssen Bayview cross-contamination precedent+2023 Q3 Bayview shutdown+FDA 483 cGMP cautionary, Oxford Biomedica $OXB.L+Q3 2024 restructure+Homology 2023 cautionary, Novartis-Kymriah Morris Plains+Q3 2024 GMP-warning-Advate 2019 precedent, Charles River Labs $CRL+Q3 2024 restructure cautionary. Cautionary: Catalent-Novo Dec-2024 $16.5B take-private-closed+FTC-DOJ HSR Q3 2024 cleared+WuXi Biologics+WuXi AppTec BIOSECURE H.R. 8333 House-Passed Sep-2024+Emergent J&J-Janssen 2021 Bayview cross-contamination+2023 Q3 Bayview shutdown+FDA 483 cGMP+Novartis-Kymriah Advate 2019 GMP-warning precedent+Sartorius Q3 2024 profit-warning+2023 Q4+bioprocessing-destocking+Charles River Q3 2024 restructure+Oxford Biomedica Q3 2024 restructure+Homology 2023+CBM Discovery Labs Q3 2024 restructure+Ch-11-avoided+National Resilience Q3 2024 restructure+2023 layoffs+Elevate Bio D1-SoftBank+Recipharm-EQT Q3 2024 restructure+Curia-GHO Q3 2024 layoffs+Corden Pharma divest exploration+Baxter-Simtra Advent-Warburg 2023 $4.25B carve-out called out.

Question 3

What FDA cGMP + Annex 1 + ICH + DSCSA + BIOSECURE + CHIPS + IRA + EO 14081 discipline do investors want to see day-one?

Accepted Answer

US FDA: FDA CDER+CBER+CDRH+ORA+21 CFR Part 210+211 cGMP+Part 4 Combination Products+Part 600 Biologics+Part 606 Blood+Part 610 General Biological Products+Part 820 QSR+Q3 2024 QMSR-ISO 13485-harmonization Feb-2026+21 CFR Part 11 Electronic Records+CDER FDORA 2022+DSCSA Nov-2024 Enforcement-Discretion Q3 2024+FDA Real Time Release Testing+PAT Process Analytical Technology+QbD Quality by Design+Continuous Manufacturing PDA TR 66. ICH+aseptic+cleanroom: ICH Q7 API+Q8 Pharmaceutical Development+Q9 Quality Risk Management+Q10 Pharmaceutical Quality System+Q11 API Development+Q12 Lifecycle+Q13 Continuous Manufacturing 2023+Q14 Analytical Procedure Development+FDA Annex 1 Manufacture of Sterile Medicinal Products EU-GMP August-2023+ISO 14644 Cleanroom+ISO 13408 Aseptic+ISO 8871 Elastomers+ISO 11607 Packaging+ISPE Baseline Guides+PDA Technical Reports+ISO 27001+SOC 2+CSV Computer System Validation+GAMP 5 Second Edition July-2022+ALCOA+Data Integrity FDA 483s+Warning Letters. Global regulators+pharmacopoeias: EudraLex Volume 4+EMA CHMP+CVMP+PRAC+CAT+COMP+PDCO+MHRA UK Post-Brexit+PMDA Japan+NMPA China+ANVISA Brazil+Health Canada+WHO PQ+USP+Ph. Eur.+JP. Industrial policy+geopolitics+trade: BIOSECURE Act H.R. 8333 House-Passed Sep-2024 WuXi Biologics+WuXi AppTec+BGI cautionary+CHIPS+Science Act 2022+IRA Drug-Pricing 2022+Medicare Negotiation+EO 14081 Bioeconomy Sep-2022+NIH+BARDA+ASPR+DoD DARPA+WHO+CEPI+GAVI+EU Critical Medicines Act 2024 proposed+Q3 2024 EU Pharmaceutical Package Reform+CTIS Clinical Trial Regulation Jan-2022+EU IVDR May-2022+MDR May-2021. Cautionary: Emergent BioSolutions J&J-Janssen 2021 Bayview Baltimore cross-contamination+2023 Q3 Bayview shutdown+FDA 483 cGMP violations precedent+Novartis-Kymriah Morris Plains+Q3 2024 GMP-warning-Advate 2019 precedent+Catalent-Novo Dec-2024 $16.5B take-private-closed+FTC-DOJ HSR Q3 2024 cleared+WuXi Biologics+WuXi AppTec BIOSECURE H.R. 8333 Sep-2024+Sartorius Q3 2024 profit-warning+2023 Q4+bioprocessing-destocking+Charles River Q3 2024 restructure+Oxford Biomedica Q3 2024 restructure+Homology 2023+CBM Q3 2024 restructure+Ch-11-avoided+National Resilience Q3 2024 restructure+2023 layoffs called out (booked-orderbook+fill-finish-batches-released+right-first-time+net-ARR+FDA 21 CFR 210+211 cGMP+Part 600 Biologics+Part 820 QSR+Q3 2024 QMSR-ISO 13485 Feb-2026+ICH Q7+Q8+Q9+Q10+Q11+Q12+Q13-Continuous-Manufacturing 2023+Q14+FDA Annex 1 Aug-2023+ISO 14644+ISO 13408+ISO 8871+ISO 11607+GAMP 5 Second Edition Jul-2022+DSCSA Nov-2024 Enforcement-Discretion Q3 2024+BIOSECURE Sep-2024 discipline day-one).

AI CDMO, CMO, Fill-Finish & Sterile-Injectables Fundraising

Raising Capital for AI CDMO, CMO, Fill-Finish & Sterile-Injectables Startups

Frequently asked questions

Related fundraising verticals (40)